Cigna to offer full coverage for 2 gene therapies

Cigna‘s health services business is introducing Embarc Benefit Protection^SM, a new offering that brings together the health services, medical management and specialty pharmacy expertise of Express Scripts, eviCore, Accredo and CuraScript SD to make breakthrough medicines more affordable and ensure access for those who need it.

Consumers will have no out of pocket payments related to the cost of the medicine and will receive personalized and expert care to assist them through their health journey.

Luxturna™ (voretigene neparvovec-rzyl), the first FDA-approved prescription gene therapy for people with inherited retinal disease, and Zolgensma^® (onasemnogene abeparvovec-xioi), a gene therapy for children under 2 years old with spinal muscular atrophy, will be the first two therapies included in the Embarc Benefit Protection solution. Additional therapies may be added in the future.

https://www.biospace.com/article/releases/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients/